Navigation Links
Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
Date:11/19/2013

ve dosing options of evolocumab in a range of at-risk patient populations."

OSLER is an ongoing open-label extension study evaluating the long-term safety and efficacy of evolocumab in patients with high cholesterol. In the first year, patients were randomized 2:1 to receive evolocumab and SOC or SOC alone.

"Many patients with high cholesterol struggle to adequately reduce their LDL-C, a significant contributor to cardiovascular disease," said Michael Koren, M.D., of the Jacksonville Center for Clinical Research. "The results from the OSLER study are encouraging as evolocumab may offer a potential treatment option for patients who cannot control their cholesterol levels."

Adverse events occurred in 81.4 percent of patients treated with evolocumab and SOC and in 73.1 percent of the SOC group. The five most common AEs in the evolocumab and SOC group compared to the SOC group were nasopharyngitis (12.2 percent vs. 9.8 percent), upper respiratory tract infections (7.7 percent vs. 7.6 percent), influenza (7.1 percent vs. 5.2 percent), arthralgia (6.9 percent vs. 4.3 percent), and back pain (6.5 percent vs. 5.4 percent). Other AEs that were reported included muscle-related events (9.2 percent vs. 9.8 percent), elevated liver function tests (1.8 percent vs. 1.6 percent), and elevated creatine kinase (1.0 percent vs. 1.9 percent) for patients treated with evolocumab and SOC compared to SOC alone, respectively. Serious AEs occurred in 7.1 percent of patients treated with evolocumab and SOC and 6.3 percent of the SOC group.

In the OSLER clinical trial, subcutaneous monthly treatment with evolocumab in combination with SOC resulted in a significant LDL-C decrease versus SOC alone in patients who previously completed one of four 12-week Phase 2 studies of evolocumab. After 52 weeks of treatment, patients who first received evolocumab in the OSLER study experienced an average of 52 percent reduction in LDL-C, as
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
2. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
3. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
4. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
5. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
6. Amgen And Servier Complete Product Collaboration Transaction
7. Amgen Announces 2013 Third Quarter Dividend
8. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
9. Amgen And Servier Announce Product Collaboration
10. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
11. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... how to produce ultra-thin "diamond nanothreads" that promise extraordinary ... today,s strongest nanotubes and polymers. A paper describing this ... Badding, a professor of chemistry at Penn State University, ... of the journal Nature Materials . , "From ... because the threads we formed have a structure that ...
(Date:9/20/2014)... September 20, 2014 HealthTronics, ... and interventional radiology products and services, has signed ... with Clinicon Corporation for its high ... portfolio of minimally invasive, mobile, surgical technology—offering more ... Under the agreement, HealthTronics will make available Clinicon’s ...
(Date:9/19/2014)... yields to disease risks, the biological characteristics people care ... as for heightthe textbook example of a complex traitattributes ... by multiple genetic and environmental influences, making it challenging ... genes, geneticists typically mate two individuals that differ in ... mouseand then study their descendents, looking for genes that ...
(Date:9/19/2014)... September 19, 2014 Follow ... potential to revolutionize the world has attracted diverse ... and small start-ups. The early years of nanotechnology ... largely due to the high risks involved, which ... earmarked for this evolving technology have been growing ...
Breaking Biology Technology:Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Want to link genes to complex traits? Start with more diversity 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
... Broadway Hotel in New York on Thursday, ... ... Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, active,immunotherapies for the treatment ... Executive Officer, will present at,the NewsMakers in the Biotech Industry investment ...
... Belgium, August 24 ThromboGenics NV (Euronext,Brussels: THR), ... a business update and its financial results for ... this period, ThromboGenics has raised,additional funds to invest ... good progress with its clinical programs. Highlights ...
... Stem cell company,Neuralstem, Inc. (OTC Bulletin Board: NRLS) ... on the American Stock Exchange(R) (Amex(R)),under the symbol CUR. ... August 27, 2007. "Moving to the Amex is ... of the continuous and significant progress the company has ...
Cached Biology Technology:Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference 2ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 2ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 3ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 4ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 5ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 6ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 7ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 8ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 9ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 10ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 11Neuralstem Shares Accepted for Trading on Amex(R) 2
(Date:9/21/2014)... T cells may have the ability to trigger an ... led by King,s College London. Although their immune system ... still be able to mount a strong immune defense, ... Medicine . , Our immune system is made up ... which play an important role in the frontline defense ...
(Date:9/19/2014)... by researchers from several Harvard University labs in ... and aspiring researchers with the intellectual raw materials ... from soft, flexible materials. , With the advent ... advances in manufacturing technology, soft robotics is emerging ... from conventional rigid robot design, but working with ...
(Date:9/19/2014)... you are a species which over thousands of years has ... to a substance that makes the cold dangerous for you. ... Enchytraeus albidus , and the cold provoking substance, called nonylphenol, ... , Nonylphenol is suspected of being a endocrine disruptor, but ... inhibits the worm,s ability to protect the cells in its ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... of Preventive Medicine (ACPM) has launched a web ... medicine the practice of changing health behaviors to ... The document summarizes scientific evidence supporting lifestyle interventions. ... such as definitions, reimbursement trends, related practice patterns, ...
... advent of the Human Genome Project an explosion of data ... demand to fine-tune genomic codes, which list the "ingredients for ... A Rutgers UniversityCamden biochemist is addressing this ... "background checks" on all known enzyme functions. Thanks to ...
... increases in obesity and associated diseases -- and fiery debates ... team has identified a new genetic mechanism that controls the ... to new treatments for obesity and type 2 diabetes, and ... people and dramatically cut health care costs. A research ...
Cached Biology News:American College of Preventive Medicine releases lifestyle medicine literature review 2Rutgers-Camden developing enzyme function database 2UCF discovery could open door to obesity, diabetes treatments 2
... The ProteoSpin Detergent Clean-up Micro Kit provides ... removal of SDS, Triton X-100 and other detergents ... spin-column chromatography using Norgens patented protein resin as ... processing 2 50 g of either acidic or ...
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... hematopoietic stem cells called monocytes. Osteoclasts resorb ... and lowering the surrounding pH to an ... mineral is then solubilized and the collagen ... primarily by Macrophage Colony-Stimulating Factor (M-CSF) and ...
Values of steady state parameters for enzyme activities are determined....
Biology Products: